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Endoscopic treatment of vesicoureteral reflux 
in pediatric patients
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Endoscopic treatment is a minimally invasive treatment for managing patients with vesicoureteral 
reflux (VUR). Although several bulking agents have been used for endoscopic treatment, dextranomer/
hyaluronic acid is the only bulking agent currently approved by the U.S. Food and Drug Administration 
for treating VUR. Endoscopic treatment of VUR has gained great popularity owing to several obvious 
benefits, including short operative time, short hospital stay, minimal invasiveness, high efficacy, low 
complication rate, and reduced cost. Initially, the success rates of endoscopic treatment have been 
lower than that of open antireflux surgery. However, because injection techniques have been developed, a 
recent study showed higher success rates of endoscopic treatment than open surgery in the treatment 
of patients with intermediate- and high-grade VUR. Despite the controversy surrounding its effectiveness, 
endoscopic treatment is considered a valuable treatment option and viable alternative to long-term 
antibiotic prophylaxis.
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Introduction
The management goals for children with vesicoureteral reflux (VUR) are to prevent 
febrile urinary tract infection (UTI) and renal scarring and to minimize patient morbidity
1-3). 
Ideally, the treatment choice should be evidence-based and may vary depending on each 
child’s age, sex, reflux grade, history of recurrent UTI, ipsilateral renal function, associated 
ureterorenal anomalies, and associated bladder/bowel dysfunction, in addition to parental 
and provider experience and preference. In general, VUR treatment can be either conservative 
or interventional and may include continuous antibiotic prophylaxis (CAP), endoscopic 
treatment, or open antireflux surgery
4).
CAP has been the cornerstone of VUR treatment since its initial success in the 
mid-1970s
5). However, CAP involves the risk of bacterial resistance accompanied by 
breakthrough UTIs and depends on patient compliance, which has been reported to be 
poor. Hensle et al.
6) revealed that only 17% of pediatric patients with VUR who were 
receiving prophylactic antibiotics were compliant with therapy. Of these patients, 58% 
had a diagnosis of a UTI within 1 year. Furthermore, several large prospective rando-
mized controlled trials have shown medical therapy to have little to no benefit in terms of 
decreasing the incidence of febrile UTI or renal scarring
3).
Open antireflux surgery remains the treatment of choice for high-grade reflux. There 
have been reports of a correlation between reflux grade and frequency of renal damage
7) 
and between reflux grade and acute photon defects
8). The various intravesical and 
extravesical techniques that have been described share the basic principle of leng  thening 
the intramural part of the ureter and have been shown to be safe, with low complication http://dx.doi.org/10.3345/kjp.2013.56.3.145
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rate and excellent success rates
9). Although open antireflux 
surgery offers a high cure rate, this procedure usually requires a 
prolonged hospital stay and is not without complications. The 
American Urological Association (AUA) reported that the rate 
of ureteral obstruction requiring opera  tion after open antireflux 
surgery was 0.3% to 9.1%, on the basis of 33 studies
10). Moreover, 
the AUA reported the persistence of VUR after open antireflux 
surgery for grade V VUR in 19.3% of the cases.
Endoscopic treatment is a minimally invasive management of 
VUR. Endoscopic subureteric injection was first described in 1981
11) 
and later popularized by O’Donnell and Puri
12). Subse  quently, several 
bulking agents have been used for endoscopic treatment, such as 
polytetrafluoroethylene (PTFE; Teflon, DuPont Co., Wilmington, 
DE, USA), bovine collagen, polyacrylate-polyalcohol copolymer 
(Vantris, Promedon, Cordoba, Argentina), polydimethylsiloxane 
(Macroplastique, Uroplasty Inc., Geleen, The Netherlands), 
and calcium hydroxyapatite (Coaptite, BioForm Medical Inc., 
Franksville, WI, USA). Currently, dextra  nomer/hyaluronic acid 
(Dx/HA; Deflux, Oceana Therapeutics Inc., Edison, NJ, USA) 
is the only bulking agent approved by the U.S. Food and Drug 
Administration (FDA) for treating VUR. Endoscopic treatment 
has increased rapidly after the approval of the Dx/HA copolymer 
for its use in the United States after 2001
13,14). Although the 
per-patient administered volumes of Dx/HA have steadily 
increased, the use of endos  copic treatment seems to have 
currently plateaued
15). Some providers may have increased the 
administered volume to treat high-grade reflux.
Materials for endoscopic treatment
1. PTFE
PTFE is one of the most widely used biomaterials in medicine. The 
medical applications of PTFE include vascular grafts, heart valves, 
and tissue replacement patches
16). PTFE was the first biomaterial 
used for endoscopic treatment of VUR and was commonly used in 
European countries owing to its relatively inexpensive price and 
long-term durability. However, injection of PTFE requires special 
equipment because of its high viscosity. The size of a PTFE molecule 
is only approximately 4–100 µm; thus, it has a high potential 
to spread to other organs. In an experi  mental model and some 
clinical studies, numerous particles of PTFE were recovered from 
the lungs and brain after PTFE injection for VUR. Although no 
adverse neurological effects have been reported clinically, some 
particles may lodge in the brain, where they can block cerebral 
microcirculation
17,18).
2. Cross-linked bovine collagen 
Collagen was intensively used in the medical industry for the 
manufacturing of cardiac valves and hemostatic agents. Cross-
linked bovine collagen (Zyplast, Inamed Co., Santa Barbara, 
CA, USA) can be injected even with a small-diameter injection 
needle and cause minimal tissue reaction when locally injected. 
Injection of this compound also induces collagen production 
by infiltrating fibroblast cells and therefore causes less inflam-
mation. Moreover, collagen particles migrate mi  nimally
16). 
Owing to these features, collagen initially seemed a promising 
substance for VUR. However, Haferkamp et al.
19) showed that the 
volume of the injected collagen decreased in long-term follow-
up. The success rate was 93% at 1 month after the injection but 
decreased to 35% after 1 year. Moreover, there have been reports 
of the development of connective tissue diseases subsequent 
to collagen injection, including sys  temic lupus erythematosus, 
polymyositis, and dermato  myositis
20).
3. Polydimethylsiloxane 
Polydimethylsiloxane is a solid, elastomeric, silicone, soft 
tissue bulking material that has been incorporated into a pa-
tented medical device called Macroplastique. The injectable 
material comprises soft, flexible, highly textured implants of 
heat-vulcanized polydimethylsiloxane suspended in a bioex-
cretable polyvinylpyrrolidone carrier hydrogel. The carrier gel 
is a pharmaceutical-grade, water-soluble, low-molecular-weight 
povidone that has been studied and safely used clinically for 
many years
21).
Polydimethylsiloxane has been found to have a mean maxi-
mum particle diameter of 209 µm
22). Because it is highly vis-
cous, its injection requires an administration gun that can 
withhold high pressure. To minimize particle migration, poly-
dimethylsiloxane is engineered to create an elastomer instead of 
the less cross-linked silicone gels or the noncross-linked silicone 
oils used in breast implants. After injection, its consistency allows 
the polydimethylsiloxane implant to be held in place. The carrier gel 
is then absorbed and exchanged for a natural reactive transudate 
into which host fibroblasts and macrophages subsequently deposit 
collagen, thus encapsulating the implant. The absorbed hydrogel 
is removed from the implantation site via reticuloendothelial 
cells and excreted unmetabolized by the kidneys
21). In animal 
experiments, silicone was found to migrate locally and dis-
tantly
23,24); therefore, the FDA did not approve its use for VUR 
treatment. In addition, it has been found that silicone particles 
cause neuropathy by inducing fibrosis around nerve cells
25). 
Because of this major side-effect, its use has greatly diminished.
4. Autologous chondrocytes
The use of autologous chondrocytes for the endoscopic treat-
ment of VUR was proposed after successful animal experiments. 
Caldamone and Diamond
26) harvested chondrocytes from ear 
cartilage and incubated them for 6 weeks. However, the need to 147 http://dx.doi.org/10.3345/kjp.2013.56.4.145
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perform 2 procedures under anesthesia, the first for harvesting 
cartilage cells for the preparation of the injection solution 
and the second for the endoscopic implantation, reduced the 
popularity of the substance. Moreover, a considerably high 
recurrence rate in children after 1 year raised a serious question 
about the reliability of this tissue-augmenting substance
16,26).
5. Calcium hydroxyapatite 
Calcium hydroxyapatite has been used as an implant for 
dental restoration and bone healing for longer than 25 years. 
It comprises smooth 75- to 125-µm spheres of synthetic calcium 
hydroxyapatite suspended in a gel composed mainly of glycerin 
and water, with a chemically modified, naturally occurring 
polysaccharide sodium carboxymethylcellulose as support
27). 
It can be easily injected with a small-diameter injection needle. 
However, although the short-term success rate of subureteric 
injection of calcium hydroxyapatite for 23 ureters was favorable, 
the 47- to 60-month long-term success rate was decreased to 
47.4%; hence, its durability was questioned. Particularly in 1 
reported case, the migration of the injected material resulted in a 
nonfunctioning kidney
28).
6. Dx/HA 
After it was introduced by Stenberg and Lackgren
29) in 1995, 
Dx/HA has been the most widely used bulking agent for the 
endoscopic treatment of VUR. It is also the most studied endo-
scopic material, and there are enough available long-term data 
to clearly understand its efficacy
16). Currently, Dx/HA is the 
only material approved by the FDA for treating VUR. Deflux 
is composed of dextran polymer microspheres and non  animal 
hyaluronic acid mixed to form a viscous gel with 2 components, 
both of which are made up of polysaccharide (sugar-based) 
molecules. Dextranomer microspheres are formed by cross-
linking dextran polymers into porous beads of 80–250 µm in 
diameter
16). After injection, dextranomer microspheres cause 
deposition of fibroblasts and collagen. Dx/HA is a biodegradable 
material that can be easily injected, with most of its molecules 
larger than 80 µm, thus having less potential of migrating to 
other organs. In addition, it is known to not cause inflammation 
and mutation. Moreover, Dx/HA can be well encapsulated and 
maintained in injected sites.
The overall success rate of Dx/HA use ranged from 68% to 92%, 
depending on the VUR grade
30-32). Kirsch et al.
31) revealed that 
the short-term results with the hydrodistention implantation 
technique (HIT) may be close to those after open antireflux 
surgery. Whether Dx/HA has long-term durability is not clear, 
but the current long-term follow-up data are insufficient. Lack  gren 
et al.
33) reported that although Dx/HA was shown to resolve reflux 
in the short-term, their 2- to 5-year long-term trace study revealed 
a recurrence rate of almost 13%.
Developments of the endoscopic treatment
The original subureteric Teflon injection (STING) procedure 
was originally designed for injecting PTFE. The suggested 
injection site is 2 to 3 mm below the affected ureteric orifice, 
at the 6 o’clock position. The needle enters the bladder mucosa 
and advances 4 to 5 mm into the submucosal plane, creating a 
mound that elongates the intramural ureter
12). This method has 
been shown to be safe and minimally invasive for VUR treat-
ment
30,33).
The modified STING procedure, later known as the HIT, was 
introduced in 2004. Kirsch et al.
31) modified this procedure by 
inserting the needle into the submucosal tunnel of the ureter 
via hydrodistention. The investigators reported a success rate of 
92% using the HIT procedure compared with the 79% using the 
conventional STING procedure, with better results in patients with 
high-grade reflux.
In recent years, the HIT procedure has been modified to include 
2 tandem intraluminal ureteric tunnel injections (double HIT)
34,35). 
Before injection, the bladder is emptied, and the ureteral orifices 
are hydrodistended and graded according to the hydro  distention 
grading system (H0–H3)
36). The first injection is made at the 6 o’clock 
position mid tunnel and coapts the proximal tunnel. A second 
injection is made at the distal aspect of the tunnel at the location 
of the ureteral orifice and serves to coapt the ureteral meatus
34). 
Kalisvaart et al.
34) evaluated 54 patients who underwent double HIT 
and revealed 93% clinical and 93% radio  graphic intermediate/
long-term success rates.
Endoscopic treatment for VUR has gained great popularity 
owing to its low invasiveness and high efficacy. Some investi-
gators have suggested endoscopic treatment as a first-line 
treatment alternative to CAP or surgical treatment
30-32,37-39). 
Several obvious benefits are driving this trend, including the 
short operation time, short hospital stay, minimal invasiveness, 
low complication rate, and reduced cost
40). Although the medical 
cost may vary, the physical and mental burdens are significantly 
decreased
41). Another advantage involves the high success rates in 
low-grade reflux, making endoscopic treatment a viable alternative 
to long-term antibiotic prophylaxis
42). This hypothesis has been 
proven in a study performed among 91 families with children 
who had reflux with a mean duration of 2 years
43). If a child 
was predicted to have VUR for up to 1 year, most parents chose 
prophylactic antibiotics with yearly voiding cystourethrography. 
However, if the duration of pro  phylactic antibiotic use were to 
exceed 3 years, 60% of the parents would choose endoscopic 
treatment over open surgery, although the child may have to 
undergo repeat injections, with a 20% risk of persistent reflux. 
Meanwhile, the increased use of endoscopic treatment have 
not resulted in decreased use of open antireflux surgery
13,14), 
indicating a shift in surgical indi  cations in some centers or http://dx.doi.org/10.3345/kjp.2013.56.3.145
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regions
37).
In a meta-analysis that examined several types of injections 
(including Dx/HA) in 8,101 ureters, primary success rates of 
78.5% for grades I and II, 72.0% for grade III, 63.0% for grade 
IV, and 51.0% for grade V reflux were demonstrated. In cases of 
failed first treatment, the second and third injections had success 
rates of 68% and 34%, respectively
44).
One major disadvantage of the endoscopic management of 
reflux is its poor therapeutic outcome in patients with high-
grade reflux as compared with open antireflux surgery; there-
fore, endoscopic treatment may not be used in this clinical 
scenario
42). Most treatment failures are due to extrusion of the 
material immediately after injection, postoperative decrease 
in volume, and migration of the implant
45). However, a recent 
study showed very high success rates repetitive injections were 
administered in children with intermediate- and high-grade VUR 
compared with those in open surgery
46).
Investigators have reported a variable success rate (50–94%)
31,47), 
indicating differences in methods and study design, including 
differences in patient selection in addition to surgeon or technical 
factors
48). Independent of the technique used, there has been a 
learning curve associated with endoscopic VUR correction
49). 
Kirsch et al.
50) reported a 60% success rate in their first 20 pa-
tients compared with the 80% success rate in their most recent 
20 patients. Herz et al.
21) achieved a success rate of 46% in 
28 refluxing ureters during the first 6 months of their study. 
In the subsequent 18 months, the overall correction rate was 
93% in 84 ureters. Using multivariate analysis, Lorenzo et al.
51) 
demonstrated that physician experience was an independent 
predictor of VUR correction rates.
There is significant dissent as to what constitutes a successful 
endoscopic treatment. In the United States, successful endoscopic 
treatment is typically defined as the absence of VUR
47,52); how-
ever, in several European studies, the presence of grade I or II 
VUR (downgrading) after injection is considered successful
33,53, 54). 
If the goal is the prevention of recurrent febrile UTIs, the clinical 
success rate is high (>90%) in most modern series. However, if 
success is defined radiologically as the absence of VUR after 1 
treatment, then the success rate falls between 50% and 93%. 
Combining these 2 definitions (i.e., no VUR and no febrile UTI 
after a single treatment) may result in an even lower success 
rate
55).
Recently, the effectiveness of CAP has been intensely dis-
cussed. Some studies comparing the conservative management 
with or without CAP suggested that there was no significant 
dif  ference between the 2 groups in patients with low-grade 
VUR
56-58). Owing to controversies, the new guideline does not 
universally recommend CAP for children with VUR. Paradoxi-
cally, “downgrading to the level of no antibiotics” can be used to 
define treatment success.
Conclusions
There are several options for managing VUR in pediatric 
patients. Treatment options should be evidence-based and 
should depend upon the condition of each patient. Endoscopic 
treatment of VUR has developed rapidly, and has replaced 
some aspects of the antibiotic treatment and open surgery. 
Many researchers have been engaged in developing new tech-
niques and safe materials. Open antireflux surgery remains 
the treatment of choice for high-grade reflux. However, en-
doscopic treatment has several advantages for grade II to IV 
reflux. Although its effectiveness for high-grade VUR has 
been inconsistent, endoscopic treatment is currently considered a 
valuable treatment option and viable alternative to long-term 
antibiotic prophylaxis.
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